Jill H Tseng1, Renee A Cowan1, Qin Zhou2, Alexia Iasonos2, Maureen Byrne1, Tracy Polcino1, Clarissa Polen-De1, Ginger J Gardner3, Yukio Sonoda3, Oliver Zivanovic3, Nadeem R Abu-Rustum3, Kara Long Roche3, Dennis S Chi4. 1. Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America. 2. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America. 3. Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America; Department of Obstetrics and Gynecology, Weill Cornell Medical College, New York, NY, United States of America. 4. Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America; Department of Obstetrics and Gynecology, Weill Cornell Medical College, New York, NY, United States of America. Electronic address: chid@mskcc.org.
Abstract
OBJECTIVES: To assess complete gross resection (CGR) rates and survival outcomes in patients with advanced ovarian cancer who underwent primary debulking surgery (PDS) during a 13-year period in which specific changes to surgical paradigm were implemented. METHODS: We identified all patients with stage IIIB-IV high-grade ovarian carcinoma who underwent PDS at our institution, with the intent of maximal cytoreduction, from 1/2001-12/2013. Patients were categorized by year of PDS based on the implementation of surgical changes to our approach to ovarian cancer debulking (Group 1, 2001-2005; Group 2, 2006-2009; Group 3, 2010-2013). RESULTS: Among 978 patients, 78% had stage IIIC disease and 89% had disease of serous histology. Carcinomatosis was found in 81%, and 60% had bulky upper abdominal disease (UAD). Compared to Group 1, those who underwent PDS during the latter 2 time periods had higher ASA scores (p < 0.001), higher-stage disease (p < 0.001), and more often had carcinomatosis (p = 0.015) and bulky UAD (p = 0.009). CGR rates for Groups 1-3 increased from 29% to 40% to 55%, respectively (p < 0.001). Five-year progression-free survival (PFS) rates increased over time (15%, 16%, and 20%, respectively; p = 0.199), as did 5-year overall survival (OS) rates (40%, 44%, and 56%, respectively; p < 0.001). On multivariable analysis, CGR was independently associated with PFS (p < 0.001) and OS (p < 0.001). CONCLUSIONS: Despite higher-stage disease and greater tumor burden, CGR rates, PFS and OS for patients who underwent PDS increased over a 13-year period. Surgical paradigm shifts implemented specifically to achieve more complete surgical cytoreduction are likely the reason for these improvements.
OBJECTIVES: To assess complete gross resection (CGR) rates and survival outcomes in patients with advanced ovarian cancer who underwent primary debulking surgery (PDS) during a 13-year period in which specific changes to surgical paradigm were implemented. METHODS: We identified all patients with stage IIIB-IV high-grade ovarian carcinoma who underwent PDS at our institution, with the intent of maximal cytoreduction, from 1/2001-12/2013. Patients were categorized by year of PDS based on the implementation of surgical changes to our approach to ovarian cancer debulking (Group 1, 2001-2005; Group 2, 2006-2009; Group 3, 2010-2013). RESULTS: Among 978 patients, 78% had stage IIIC disease and 89% had disease of serous histology. Carcinomatosis was found in 81%, and 60% had bulky upper abdominal disease (UAD). Compared to Group 1, those who underwent PDS during the latter 2 time periods had higher ASA scores (p < 0.001), higher-stage disease (p < 0.001), and more often had carcinomatosis (p = 0.015) and bulky UAD (p = 0.009). CGR rates for Groups 1-3 increased from 29% to 40% to 55%, respectively (p < 0.001). Five-year progression-free survival (PFS) rates increased over time (15%, 16%, and 20%, respectively; p = 0.199), as did 5-year overall survival (OS) rates (40%, 44%, and 56%, respectively; p < 0.001). On multivariable analysis, CGR was independently associated with PFS (p < 0.001) and OS (p < 0.001). CONCLUSIONS: Despite higher-stage disease and greater tumor burden, CGR rates, PFS and OS for patients who underwent PDS increased over a 13-year period. Surgical paradigm shifts implemented specifically to achieve more complete surgical cytoreduction are likely the reason for these improvements.
Authors: Neil S Horowitz; Austin Miller; Bunja Rungruang; Scott D Richard; Noah Rodriguez; Michael A Bookman; Chad A Hamilton; Thomas C Krivak; G Larry Maxwell Journal: J Clin Oncol Date: 2015-02-09 Impact factor: 44.544
Authors: Taymaa May; Alon Altman; Jacob McGee; Lin Lu; Wei Xu; Kelly Lane; Prafull Ghatage; Barry Rosen Journal: Int J Gynecol Cancer Date: 2018-06 Impact factor: 3.437
Authors: Philipp Harter; Zelal M Muallem; Christine Buhrmann; Dietmar Lorenz; Christine Kaub; Rita Hils; Stefan Kommoss; Florian Heitz; Alexander Traut; Andreas du Bois Journal: Gynecol Oncol Date: 2011-03-17 Impact factor: 5.482
Authors: Vasileios D Sioulas; Maria B Schiavone; David Kadouri; Oliver Zivanovic; Kara Long Roche; Roisin O'Cearbhaill; Nadeem R Abu-Rustum; Douglas A Levine; Yukio Sonoda; Ginger J Gardner; Mario M Leitao; Dennis S Chi Journal: Gynecol Oncol Date: 2017-02-21 Impact factor: 5.482
Authors: Oliver Zivanovic; Eric L Eisenhauer; Qin Zhou; Alexia Iasonos; Paul Sabbatini; Yukio Sonoda; Nadeem R Abu-Rustum; Richard R Barakat; Dennis S Chi Journal: Gynecol Oncol Date: 2007-11-13 Impact factor: 5.482
Authors: Andreas du Bois; Alexander Reuss; Eric Pujade-Lauraine; Philipp Harter; Isabelle Ray-Coquard; Jacobus Pfisterer Journal: Cancer Date: 2009-03-15 Impact factor: 6.860
Authors: Andrew Bryant; Shaun Hiu; Patience T Kunonga; Ketankumar Gajjar; Dawn Craig; Luke Vale; Brett A Winter-Roach; Ahmed Elattar; Raj Naik Journal: Cochrane Database Syst Rev Date: 2022-09-26
Authors: Thomas Boerner; Olga T Filippova; Andrew J Chi; Alexia Iasonos; Qin C Zhou; Kara Long Roche; Oliver Zivanovic; Bernard J Park; James Huang; David R Jones; Nadeem R Abu-Rustum; Ginger Gardner; Yukio Sonoda; Dennis S Chi Journal: Gynecol Oncol Date: 2020-08-10 Impact factor: 5.482
Authors: Olga T Filippova; Amy L Tin; Joanne Alonso; Andrew J Vickers; William P Tew; Ginger J Gardner; Yukio Sonoda; Kara Long Roche; Oliver Zivanovic; Dennis S Chi; Armin Shahrokni Journal: Gynecol Oncol Date: 2021-03-25 Impact factor: 5.304
Authors: Marcia Hall; Konstantinos Savvatis; Katherine Nixon; Maria Kyrgiou; Kuhan Hariharan; Malcolm Padwick; Owen Owens; Paula Cunnea; Jeremy Campbell; Alan Farthing; Richard Stumpfle; Ignacio Vazquez; Neale Watson; Jonathan Krell; Hani Gabra; Gordon Rustin; Christina Fotopoulou Journal: Ann Surg Oncol Date: 2019-06-26 Impact factor: 5.344
Authors: Deepa M Narasimhulu; Aneesa Thannickal; Amanika Kumar; Amy L Weaver; Michaela E McGree; Carrie L Langstraat; William A Cliby Journal: Gynecol Oncol Date: 2020-12-31 Impact factor: 5.482
Authors: S T Paijens; A Vledder; D Loiero; E W Duiker; J Bart; A M Hendriks; M Jalving; H H Workel; H Hollema; N Werner; A Plat; G B A Wisman; R Yigit; H Arts; A J Kruse; N M de Lange; V H Koelzer; M de Bruyn; H W Nijman Journal: Oncoimmunology Date: 2021-06-06 Impact factor: 8.110